Cogent Biosciences, Inc. UMRX
No live quote for UMRX yet.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 5.00
- Target (low)
- 4.00
- Target (mean)
- 5.00
- Target (high)
- 6.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy1
- Buy2
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 2
- 2 months ago 2
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.19 | -0.34 – -0.04 | -0.39 | +51.3% | 0 | 0.0% | 2 |
| Next quarter | -0.04 | -0.05 – -0.04 | 0.07 | -157.1% | 0 | 0.0% | 2 |
| Current year | -0.54 | -0.83 – -0.25 | -1.04 | +48.1% | 7.58M | -66.3% | 2 |
| Next year | -0.20 | -0.25 – -0.16 | -0.54 | +63.0% | 0 | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 2020 | Jefferies | Initiated | — | Buy |
| Jul 6, 2020 | Wedbush | Upgrade | Neutral | Outperform |
| Mar 26, 2020 | H.C. Wainwright | Maintained | — | Buy |
| Mar 3, 2020 | Wedbush | Downgrade | Outperform | Neutral |
| Mar 2, 2020 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Nov 26, 2019 | Morgan Stanley | Maintained | — | Overweight |
| Feb 25, 2019 | Cowen & Co. | Initiated | — | Market Perform |
| Dec 19, 2018 | H.C. Wainwright | Initiated | — | Buy |
| Oct 10, 2018 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 13, 2018 | Wedbush | Maintained | Outperform | Outperform |
| Apr 22, 2018 | Wedbush | Initiated | — | Outperform |
| Apr 22, 2018 | Morgan Stanley | Initiated | — | Overweight |
| Apr 22, 2018 | Cowen & Co. | Initiated | — | Market Perform |
| Apr 22, 2018 | SunTrust Robinson Humphrey | Initiated | — | Buy |